All In Biotech

Drug Trial Radar · NCT02924766

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

A Safety and Pharmacokinetics Study of Niraparib Plus Androgen Receptor-Targeted Therapy (Apalutamide or Abiraterone Acetate Plus Prednisone) in Men With Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Jul 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

34

Actual

Start

Oct 3, 2016

Primary completion

Jul 18, 2019

Study completion Jul 19, 2019

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Oct 5, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and pharmacokinetics of niraparib when administered in combination with an androgen receptor (AR)-targeted therapy (apalutamide or abiraterone acetate plus prednisone) in adult men with metastatic castration resistant prostate cancer (mCRPC) who may or may not have deoxyribonucleic acid (DNA)-repair anomalies.

Conditions

  • Prostatic Neoplasms

Interventions

  • NiraparibDrug

    Participants will start with niraparib 200 mg once daily.

  • ApalutamideDrug

    Participants will receive apalutamide 240 mg (4\*60 mg) once daily orally.

  • Abiraterone AcetateDrug

    Participants will receive 1000 mg (4\*250mg) once daily.

  • PrednisoneDrug

    Participants will receive 10 mg (1\*5 mg twice daily).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine Recommended Phase 2 dose (RP2D) of Niraparib in Combination With 240 milligram (mg) Apalutamide or 1,000 mg Abiraterone Acetate Plus 10 mg Prednisone (5 mg Twice Daily) in Part 1Time frame: Up to 56 days
  2. Number of Participants With Incidence and Severity of Adverse Events (Part 2)Time frame: Up to 30 days after last dose

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    West Hollywood, California

  • Site not named

    Louisville, Kentucky

  • Site not named

    Portland, Oregon

  • Site not named

    Myrtle Beach, South Carolina

  • Site not named

    Vancouver, British Columbia, Canada

  • Site not named

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.